DGAP-News: Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
DGAP-News: Sernova Corp.
/ Key word(s): Study results/Conference
LONDON, ONTARIO - December 16, 2021 - Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential 'functional cure' for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that Dr. Piotr Witkowski, principal investigator of Sernova's Phase I/II clinical trial will present updated interim results from the ongoing safety, tolerability and efficacy study of Sernova's Cell Pouch(TM) in a poster session at the American Society of Transplant Surgeons (ASTS) 22nd Annual "State of the Art" Winter Symposium on January 13, 2022. Dr. Witkowski's presentation entitled, A Modified Approach for Improved Islet Allotransplantation into the Pre-vascularized Sernova Cell Pouch(TM) device-preliminary results of the phase I and II clinical study at University of Chicago, will be presented to more than 600 transplant professionals as part of Abstract Session A, starting at 5:30 PM. Further details on the program and registration can be found on the ASTS Winter Symposium website: https://asts.org/events-meetings/winter-symposium The ASTS Winter Symposium is the same conference where, in January 2021, Dr. Witkowski presented positive preliminary safety and efficacy data indicating that Sernova's Cell Pouch(TM) transplanted with insulin producing cells in patients with type 1 diabetes showed persistent islet function and clinically meaningful improvement in measures of glucose control. The American Society of Transplant Surgeons represents approximately 1,900 professionals, regulatory authorities and pharmaceutical representatives dedicated to excellence in transplantation surgery. ASTS advances the art and science of transplant surgery through patient care, research, education, and advocacy. ABOUT SERNOVA The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago. Positive initial results have been presented at several international scientific conferences. FOR FURTHER INFORMATION, PLEASE CONTACT: Christopher Barnes FORWARD-LOOKING INFORMATION
16.12.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Sernova Corp. |
700 Collip Circle, Ste 114 | |
N6G 4X8 London | |
Canada | |
Internet: | https://www.sernova.com/contact/ |
EQS News ID: | 1258867 |
End of News | DGAP News Service |
|
1258867 16.12.2021
Sernova Corp. Aktie
Wenige Einschätzungen bei Sernova Corp. lassen noch kein klares Bild zu.
Mit einem Kursziel von 12 € für Sernova Corp., würde dies eine mehr als zweifache Steigerung des aktuellen Kurses von 0.22 € bedeuten.